2021
Randomized trial of exercise on depressive symptomatology and brain derived neurotrophic factor (BDNF) in ovarian cancer survivors: The Women's Activity and Lifestyle Study in Connecticut (WALC)
Cartmel B, Hughes M, Ercolano EA, Gottlieb L, Li F, Zhou Y, Harrigan M, Ligibel JA, von Gruenigen VE, Gogoi R, Schwartz PE, Risch HA, Lu L, Irwin ML. Randomized trial of exercise on depressive symptomatology and brain derived neurotrophic factor (BDNF) in ovarian cancer survivors: The Women's Activity and Lifestyle Study in Connecticut (WALC). Gynecologic Oncology 2021, 161: 587-594. PMID: 33773809, PMCID: PMC8085084, DOI: 10.1016/j.ygyno.2021.02.036.Peer-Reviewed Original ResearchConceptsOvarian cancer survivorsCES-D scoresCancer survivorsOvarian cancerDepressive symptomatologyAC armStage III/IV ovarian cancerBaseline CES-D scoreTrial of exerciseEpidemiologic Studies Depression ScaleOvarian cancer patientsEffects of exerciseSix-month changesPrevalent mental disordersLower depressive symptomsExercise armSerum BrainNeurotrophin factorRandomized trialsNeurotrophic factorCancer patientsLifestyle StudyDepression ScalePhysical activityDepressive symptoms
2011
MicroRNA let-7a: A potential marker for selection of paclitaxel in ovarian cancer management
Lu L, Schwartz P, Scarampi L, Rutherford T, Canuto EM, Yu H, Katsaros D. MicroRNA let-7a: A potential marker for selection of paclitaxel in ovarian cancer management. Gynecologic Oncology 2011, 122: 366-371. PMID: 21571355, DOI: 10.1016/j.ygyno.2011.04.033.Peer-Reviewed Original ResearchConceptsLow let-7aDisease progressionLet-7aSurvival analysisEpithelial ovarian cancer patientsPlatinum-based chemotherapyOvarian cancer managementOvarian cancer patientsAddition of paclitaxelType of treatmentLet-7a expressionOvarian cancer resistanceOverall survivalDifferent chemotherapyEOC patientsPatient survivalSurvival outcomesDisease stageOvarian tumorsCancer patientsTumor gradeDisease outcomeCancer managementBetter survivalEOC survival
2008
Klotho Expression in Epithelial Ovarian Cancer and its Association with Insulin-Like Growth Factors and Disease Progression
Lu L, Katsaros D, Wiley A, de la Longrais IA, Puopolo M, Yu H. Klotho Expression in Epithelial Ovarian Cancer and its Association with Insulin-Like Growth Factors and Disease Progression. Cancer Investigation 2008, 26: 185-192. PMID: 18259951, DOI: 10.1080/07357900701638343.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCystadenocarcinoma, SerousDisease ProgressionEpithelial CellsFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticGlucuronidaseHumansInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IInsulin-Like Growth Factor IIKlotho ProteinsMiddle AgedNeoplasm StagingOvarian NeoplasmsPrognosisReverse Transcriptase Polymerase Chain ReactionRNA, NeoplasmSurvival RateConceptsEpithelial ovarian cancerKlotho expressionOvarian cancer progressionDisease progressionOvarian cancerCox proportional hazards regression modelTumor tissueProportional hazards regression modelsCancer progressionInsulin-like growth factorResidual tumor sizeAction of IGFOvarian cancer patientsExpression of IGFHazards regression modelsOvarian cancer prognosisEpithelial ovarian cancer progressionExpression of totalFresh tumor tissueWarrants further elucidationUnderwent surgeryIGFBP-3Patient ageClinical followTumor histology
2007
IGF-I in epithelial ovarian cancer and its role in disease progression
Brokaw J, Katsaros D, Wiley A, Lu L, Su D, Sochirca O, de la Longrais IA, Mayne S, Risch H, Yu H. IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors 2007, 25: 346-354. PMID: 18236213, DOI: 10.1080/08977190701838402.Peer-Reviewed Original ResearchConceptsIGF-I transcriptsDisease progressionOvarian cancerTumor progressionEpithelial ovarian cancer patientsIGF-I mRNA expressionInsulin-like growth factorParacrine/autocrine regulationIGF-I activityEpithelial ovarian cancerIGF-I actionOvarian cancer patientsFresh tumor samplesIGF-I expressionIGF-I mRNAOvarian cancer progressionEnzyme-linked immunosorbentParacrine/autocrineTotal IGFFree IGFClinicopathologic featuresCA polymorphismCancer patientsReal-time PCRElevated risk